金宇生物技术股份有限公司 2024年度审计委员会履职情况报告 根据《上市公司治理准则》《上海证券交易所上市公司自律监管指引第1号— —规范运作》《公司章程》和《公司审计委员会实施细则》等有关规定, 金宇生 物技术股份有限公司（以下简称"公司"）董事会审计委员会委员本着勤勉尽责 的原则，认真履行了审计监督职责，现就公司董事会审计委员会2024年度工作情 况报告如下： 一、董事会审计委员会基本情况 公司第十一届董事会审计委员会由3名成员组成，其中独立董事2名，非独立 董事1名，由独立董事申嫦娥担任召集人，吴振平、高日明担任委员。审计委员 会各成员均具备能够胜任审计委员会工作职责的专业知识和经验，其中召集人由 具有注册会计师资格的会计专业独立董事担任，符合上海证券交易所的规定及相 关制度的要求。 二、2024年度审计委员会会议召开情况 2024年度，公司董事会审计委员会共召开4次会议，审计委员会委员均亲自 出席以上会议，审议议案均以全体委员一致同意的表决结果通过。会议就年度审 计报告、定期报告、内部控制评价审计、续聘审计机构等事项进行了审议，为董 事会科学决策提供了保障。会议具体内容如下： | 召开日期 | 会议内 ...

证券代码：600201 证券简称：生物股份 公告编号：临 2025-017 金宇生物技术股份有限公司 关于使用闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 委托理财品种：安全性高、流动性好、固定或浮动收益类的现金管理理财 产品，包括但不限于现金类理财产品、固定收益类理财产品、权益类理财产品、 保本型理财产品、混合类理财产品、商品及金融衍生品类理财产品等 ● 委托理财期限：投资期限为第十一届董事会第十八次会议审议通过后一年 内有效 公司拟进行委托理财的金融机构与公司不存在关联关系，不构成关联交易。 一、现金管理概述 为提高金宇生物技术股份有限公司（含控股子公司、控股孙公司）（以下简称 "公司"）自有资金使用效率，在做好日常资金调配、保证正常生产经营所需资金 不受影响的基础上，并在严格控制风险和充分信息披露的前提下，公司结合自身 资金情况拟使用不超过人民币 5 亿元的闲置自有资金适时购买单笔期限不超过 12 个月的风险可控的理财产品。上述资金额度在决议有效期内可以滚动使用，并授 ...

关于金宇生物技术股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位：金宇生物技术股份有限公司 审计单位：致同会计师事务所（特殊普通合伙） 联系电话：010-85665588 关于金宇生物技术股份有限公司 非经营性资金占用及其他关联 资金往来的专项说明 致同会计师事务所(特殊普通合伙) on and 关于金字生物技术股份有限公司 非经营性资金占用及其他关联资金往来的专项说明 致同专字(2025) 第 441A009988 号 中国注册会计师 金字生物技术股份有限公司全体股东: 我们接受金字生物技术股份有限公司(以下简称"生物股份公司")委 托,根据中国注册会计师执业准则审计了生物股份公司 2024年12月 31日的合 并及公司资产负债表,2024年度合并及公司利润表、合并及公司现金流量表, 合并及公司股东权益变动表和财务报表附注,并出具了数同审字(2025)第 441A016663号无保冒意见审计担告。 极据《上市公司监管指引第8号 -- 上市公司资金往来,对外担保的监管 要求》等有关规定,生物股份公司编制了本专项说明所附的金字生物技术股 ...

独立董事提名人声明与承诺 提名人金宇生物技术股份有限公司董事会，现提名范红结为 金宇生物技术股份有限公司第十二届董事会独立董事候选人，并 已充分了解被提名人职业、学历、职称、详细的工作经历、全部 兼职、有无重大失信等不良记录等情况。被提名人已同意出任金 宇生物技术股份有限公司第十二届董事会独立董事候选人（参见 该独立董事候选人声明）。提名人认为，被提名人具备独立董事 任职资格，与金宇生物技术股份有限公司之间不存在任何影响其 独立性的关系，具体声明并承诺如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、 行政法规、规章及其他规范性文件，具有 5 年以上法律、经济、 会计、财务、管理或者其他履行独立董事职责所必需的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培训 证明材料。 1 条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部 辞去公职或者退（离）休后担任上市公司、基金管理公司独立董 事、独立监事的通知》的规定（如适用）； （五）中共中央组织部《关于进一步规范党政领导干部在企 业兼职（任职）问题的意见》的相关规定（如适用）； 二、被提名人任职资格符合下列法律、行政法 ...

证券代码：600201 证券简称：生物股份 公告编号：临 2025-016 金宇生物技术股份有限公司 关于为子公司银行综合授信提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、担保情况概述 公司于 2025 年 4 月 23 日召开的第十一届董事会第十八次会议和第十一届监 事会第十六次会议审议通过了《关于公司为子公司银行综合授信提供担保的议案》。 公司本次拟担保总额不超过人民币 60,000 万元，其中拟为全资子公司金宇保灵、 扬州优邦提供合计金额不超过人民币 40,000 万元的银行综合授信担保，拟为控股 子公司辽宁益康提供金额不超过人民币 20,000 万元的银行综合授信担保。具体担 保金额及担保期限以实际签署相关担保合同为准，上述担保事项尚需公司股东大 会审议批准。 二、被担保人基本情况 （一）公司名称：金宇保灵生物药品有限公司 被担保人名称：金宇保灵生物药品有限公司（以下简称"金宇保灵"） 扬州优邦生物药品有限公司（以下简称"扬州优邦"） 辽宁益康生物股份有限公司（以下简称"辽宁益康" ...

金宇生物技术股份有限公司对会计师事务所 2024 年度履职情况的评估报告 根据财政部、国务院国资委及中国证监会颁布的《国有企业、上市公司选聘 会计师事务所管理办法》，上海证券交易所颁布的《上海证券交易所上市公司自 律监管指引第1号——规范运作》等法律法规的要求，金宇生物技术股份有限公 司（以下简称"公司"或"本公司"）对聘请的2024年度财务及内部控制审计机 构，即致同会计师事务所（特殊普通合伙）（以下简称"致同所"）在2024年的 履职情况进行了评估，具体情况如下： 一、会计师事务所基本情况 1、基本情况 （1）机构名称：致同会计师事务所（特殊普通合伙） （2）成立日期：1981年，致同会计师事务所（特殊普通合伙）前身是成立 于1981年的北京会计师事务所，2011年12月22日经北京市财政局批准转制为特殊 普通合伙，2012年更名为致同会计师事务所（特殊普通合伙）。 （3）组织形式：特殊普通合伙 （4）注册地址：北京市朝阳区建国门外大街22号赛特广场五层 （5）2024年度末合伙人数量239人、注册会计师人数1359人、签署过证券服 务业务审计报告的注册会计师人数400人。 （6）2023年度经审计的业务 ...

证券代码：600201 证券简称：生物股份 公告编号：临 2025-020 金宇生物技术股份有限公司 关于修订《公司章程》及其他制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 金宇生物技术股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开第 十一届董事会第十八次会议，审议通过了《关于修订<公司章程>及其他制度的议 案》。具体情况如下： 一、公司注册资本变更情况 2025 年 4 月 23 日，公司召开第十一届董事会第十八次会议，审议通过了《关 于回购注销 2023 年员工持股计划部分股票的议案》，鉴于 2023 年员工持股计划首 次授予部分第二个解锁期解锁条件未成就、6 名持有人因个人原因离职不再具备员 工持股计划持有人资格等原因，其对应未解锁的权益份额不得解锁，对应的标的股 票数量 862.14 万股予以回购注销。本次回购注销 2023 年员工持股计划部分股票后， 公司注册资本由人民币 1,120,369,226 元变更为 1,111,747,826 元，公司股份总数由 1,120,369,2 ...

关于金宇生物技术股份有限公司 非经营性资金占用及其他关联 资金往来的专项说明 型机械发)出名属信击分 场 5 层 邮编 1000 86 10 8566 5588 86 10 8566 5120 arantthornton.cr 关于金宇生物技术股份有限公司 非经营性资金占用及其他关联资金往来的专项说明 致同专字(2025)第 441A009988 号 金宇生物技术股份有限公司全体股东: 我们接受金宇生物技术股份有限公司(以下简称"生物股份公司")委 托,根据中国注册会计师执业准则审计了生物股份公司 2024年 12月 31日的合 并及公司资产负债表,2024年度合并及公司利润表、合并及公司现金流量表、 合并及公司股东权益变动表和财务报表附注,并出具了致同审字(2025)第 441A016663 号无保留意见审计报告。 根据《上市公司监管指引第8号——上市公司资金往来、对外担保的监管 要求》等有关规定,生物股份公司编制了本专项说明所附的金宇生物技术股 份有限公司 2024 年度非经营性资金占用及其他关联资金往来情况汇总表（以 下简称"汇总表"）。 致同会计师事务所（特殊普通合伙） 目 录 关于金字生物技术股份有 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 351,572,845.58, representing a year-on-year increase of 1.06% compared to CNY 347,901,401.91 in the same period last year[4] - Net profit attributable to shareholders decreased by 27.57% to CNY 76,481,084.90 from CNY 105,586,820.64 in the previous year[4] - The net profit after deducting non-recurring gains and losses fell by 38.09% to CNY 59,015,598.31, down from CNY 95,324,670.79[4] - Basic earnings per share were CNY 0.07, a decrease of 30.00% from CNY 0.10 in the previous year[5] - The weighted average return on net assets was 1.44%, down from 1.95% in the previous year, a decrease of 0.51 percentage points[5] - The total comprehensive income increased to ¥118,882,968.21 from ¥109,828,615.86, marking an increase of about 8.5% year-over-year[19] Cash Flow and Assets - The net cash flow from operating activities decreased by 42.62% to CNY 26,218,397.99, compared to CNY 45,691,311.67 in the same period last year[4] - Current assets as of March 31, 2025, totaled RMB 2,098,516,975.45, down from RMB 2,191,397,901.49 as of December 31, 2024, indicating a decrease of about 4.23%[14] - Cash and cash equivalents decreased to RMB 1,009,736,405.59 from RMB 1,139,534,619.01, representing a decline of approximately 11.39%[14] - Total assets at the end of the reporting period were CNY 6,698,922,549.94, a decrease of 0.97% from CNY 6,764,669,055.34 at the end of the previous year[5] - Total liabilities decreased to RMB 1,291,702,099.76 from RMB 1,349,290,645.97, a reduction of approximately 4.26%[16] - The cash and cash equivalents at the end of the period decreased to ¥697,642,390.75 from ¥1,135,949,930.04, a drop of approximately 38.6%[23] Shareholder Equity and Non-Recurring Items - Shareholders' equity attributable to shareholders decreased by 0.20% to CNY 5,303,456,826.89 from CNY 5,314,336,328.75 at the end of the previous year[5] - The company reported non-recurring gains and losses totaling CNY 17,465,486.59 for the period[7] - The company reported other comprehensive income after tax of ¥41,680,353.86, significantly higher than ¥3,297,272.18 from the previous period[19] Operational Costs and Expenses - The total operating costs increased to ¥283,520,948.56 from ¥230,815,022.46, representing a growth of approximately 22.8% year-over-year[18] - The company's management reported an increase in research and development expenses to ¥39,703,032.62 from ¥31,490,190.73, an increase of about 26.1% year-over-year[18] Market Conditions and Strategic Insights - The decline in net profit and cash flow was primarily attributed to intensified industry competition and adjustments in marketing strategies[7] - There were no significant new strategies or product developments mentioned during the earnings call[12]

Financial Performance - The company's operating revenue for 2024 was CNY 1,255,455,757.88, a decrease of 21.45% compared to CNY 1,598,225,460.25 in 2023[22]. - The net profit attributable to shareholders for 2024 was CNY 108,985,186.46, down 61.57% from CNY 283,630,790.16 in 2023[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 49,487,344.61, a decline of 80.55% compared to CNY 254,459,867.96 in 2023[22]. - The net cash flow from operating activities for 2024 was CNY 289,552,214.10, a decrease of 30.20% from CNY 414,833,263.67 in 2023[22]. - The total assets at the end of 2024 were CNY 6,764,669,055.34, down 1.57% from CNY 6,872,581,837.59 at the end of 2023[22]. - Basic earnings per share fell by 61.54% to CNY 0.10, and the diluted earnings per share were not disclosed[24]. - The weighted average return on equity decreased to 1.95%, down 3.48 percentage points from the previous year[24]. - The company reported a significant decline in sales volume for several key products, including a 40.74% drop in sales of live pig fever vaccine[58]. Research and Development - The company maintained a high level of R&D investment, with CNY 179 million allocated to original product development, accounting for 14.25% of total revenue[33]. - The company has established multiple R&D platforms, including a national engineering laboratory for veterinary vaccines, enhancing research efficiency and innovation capabilities[44]. - The company is focusing on innovative vaccine technologies, including mRNA vaccines, to address critical challenges in the aquaculture sector[33]. - The company has developed a unique combination of vaccines for brucellosis, significantly reducing the incidence of the disease in livestock and humans[35]. - The company has received national recognition for its intelligent manufacturing and digital transformation initiatives, including being designated as an AI production demonstration base[35]. - The company is exploring advanced technologies such as mRNA vaccines and multi-valent vaccines to address critical animal diseases[47]. Market and Industry Trends - The domestic animal health market has grown from RMB 41.213 billion in 2013 to RMB 69.651 billion in 2023, with the veterinary biological products market increasing from RMB 9.4 billion to RMB 16.276 billion[36]. - The average price of live pigs in 2024 is approximately RMB 17.08 per kilogram, reflecting a year-on-year increase of 10.9%[37]. - The national scale of pig farming is expected to exceed 70% by 2024, indicating a trend towards increased concentration and specialization in the industry[37]. - The animal health industry is experiencing steady growth, with a compound annual growth rate (CAGR) of 6.45% in output value and 6.16% in sales over the past decade, despite some downturns in 2018 and 2022[98]. Corporate Governance - The company conducted 2 shareholder meetings during the reporting period, ensuring equal rights for all shareholders, particularly minority shareholders[109]. - The board of directors held 6 meetings, enhancing decision-making capabilities through training on relevant laws and regulations[109]. - The supervisory board convened 5 times, ensuring compliance with financial and operational regulations to protect shareholder interests[110]. - The company emphasizes information disclosure and investor relations, ensuring equal access to information for all shareholders[110]. - The company has established a commitment to maintain operational independence from its controlling shareholders[175]. Environmental Responsibility - The company has invested CNY 1,384.04 million in environmental protection during the reporting period[150]. - The company has implemented an annual self-monitoring plan for wastewater, waste gas, and noise, with online automatic monitoring for key pollutants[161]. - The company has developed a steam waste heat recovery project to enhance energy efficiency and reduce carbon emissions[168]. - The company has established a water reuse pool for irrigation and cleaning purposes, promoting resource conservation[169]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[164]. Employee Engagement and Compensation - The total number of employees in the parent company and major subsidiaries is 1,740, with 1,714 in subsidiaries and 26 in the parent company[131]. - The company has a strategic focus on expanding its employee stock ownership plan to enhance employee engagement and retention[115]. - The total compensation for the chairman during the reporting period was 130.27 million yuan, while the vice chairman and president received 118.84 million yuan[115]. - The company emphasizes a "get and share" philosophy in its compensation policy, encouraging performance-driven rewards to enhance market competitiveness[132]. Financial Management - The company has recognized an impairment provision of CNY 2,595,022.42 for the investment product due to the inability to redeem on time, influenced by various internal and external factors in the real estate industry[191]. - The company has invested CNY 45,773,885.46 in broker financial products, with an outstanding balance of CNY 43,330,560.93[189]. - The company has committed to maintaining financial independence and a complete labor management system, ensuring no overlap with controlled entities[174]. - The company will ensure compliance with relevant laws and regulations regarding shareholding and stock issuance[178].